• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 419674 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1418875524 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1418875524 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Buyers Accumulating Shares of Spectrum Pharmaceuticals on 1.2x Above-Average Volume (SPPI)

Published on Thu, 01/10/2013 - 14:13
By Peter Chu

Shares of Spectrum Pharmaceuticals are trading up 3.1% to $13.00 today on above average volume. Today's volume of 1.1 million shares tops the average 30-day volume of 918,000 shares. Spikes in volume can validate a breakout or signify a potential turning point.

Potential upside of 70.8% exists for Spectrum Pharmaceuticals, based on a current level of $13.00 and analysts' average consensus price target of $22.20. The stock should discover initial support at its 200-day moving average (MA) of $12.20 and subsequent support at its 50-day MA of $11.29.

In the past 52 weeks, shares of Spectrum Pharmaceuticals have traded between a low of $9.31 and a high of $17.48 and are now at $13.00, which is 40% above that low price. Over the past week, the 200-day moving average (MA) has remained constant while the 50-day MA has advanced 0.4%.

Spectrum Pharmaceuticals Inc. develops in-licensed drugs for the treatment and supportive care of cancer patients. The Company's satraplatin is an oral, anti-cancer drug. Spectrum's Elsamitrucin targets non-Hodgkin's lymphoma, and Neoquin is being studied in the treatment of superficial bladder cancer. Spectrum also has a pipeline of pre-clinical neurological drug candidates.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Shares of ViewPoint Financial Fall to a ...

ViewPoint Financial (NASDAQ:VPFG) traded today at a new 52-week low of $21.11. This ne ...

Shares of UQM Technologies Have Fallen B...

Shares of UQM Technologies (AMEX:UQM) traded at a new 52-week low today of $0.86. Appr ...

Shares of Terex Have Fallen Below Previo...

Shares of Terex (NYSE:TEX) traded at a new 52-week low today of $25.40. So far today a ...

Sun Communities: The Winning Streak Cont...

Shares of Sun Communities (NYSE:SUI) traded at a new 52-week high today of $60.92. So ...

Watch for Continued Losses in Shares of ...

Renesola (NYSE:SOL) traded today at a new 52-week low of $1.21. Approximately 1.1 mill ...

Solera Holdings Looks to Continue to Tra...

Solera Holdings (NYSE:SLH) traded today at a new 52-week low of $45.69. Approximately ...

SAIFUN SEMICONDUCTOR Looks to Continue t...

SAIFUN SEMICONDUCTOR (NASDAQ:SFUN) traded today at a new 52-week low of $6.78. So far ...

Shares of Select Comfort Rise Above Prev...

Shares of Select Comfort (NASDAQ:SCSS) traded at a new 52-week high today of $27.13. T ...